Research ArticleAccepted Articles
The minimal erosive volume needed for radiographic identification of erosions in the metacarpophalangeal joints in patients with rheumatoid arthritis.
Rasmus Klose-Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, Bente Langdah, Anna Zejden, Jesper Thygesen, Kresten Krarup Keller and Ellen-Margrethe Hauge
The Journal of Rheumatology November 2022, jrheum.220623; DOI: https://doi.org/10.3899/jrheum.220623
Rasmus Klose-Jensen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Josephine Therkildsen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Anne-Birgitte Garm Blavnsfeldt
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Bente Langdah
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Anna Zejden
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Jesper Thygesen
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Kresten Krarup Keller
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
Ellen-Margrethe Hauge
Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Medicine, Aarhus University, Aarhus, Denmark; Department of Endocrinology and Internal Medicine, Aarhus University, Aarhus, Denmark; Department of Radiology, Aarhus University Hospital, Aarhus, Denmark; Department of Clinical Engineering, Central Denmark Region, CO Aarhus University Hospital, Aarhus, Denmark. FUNDING: The study has been financially supported by Aarhus University, The Danish Rheumatism Association, Novo Nordic Foundation, Becket foundation and A.P. Møller foundation. The funding sources did not have any role in the collection, analysis and interpretation of data. The Financial contributors did not influence the study design, collection, analysis, and interpretation of data, the writing of the manuscript or in the decision to submit the manuscript for publication. CONFLICTS OF INTEREST: Ellen-Margrethe Hauge reports personal fees from MSD, personal fees from Pfizer, personal fees from UCB, personal fees from Sobi, grants from Roche, grants from Novartis, outside the submitted work. Bente Langdahl reports personal fees from Eli Lilly, Amgen, UCB, Gilead, and Gideon- Richter and grants from Novo Nordisk and Amgen outside the submitted work. Rasmus Klose- Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, and Kresten Krarup Keller have no conflicts of interest to declare. ETHICAL APPROVAL: The Ethics Committee of Medical Research in Central Denmark Region(1-10-72-437-17) and the Danish Data Protection Agency(1-16-02-33-18) approved the study. The study was registered at ClinicalTrials.gov(). All patients gave informed written consent before inclusion, and the study was performed in agreement with the Declaration of Helsinki. CORRESPONDENCE TO: Rasmus Klose-Jensen, PhD & MD. Department of Rheumatology, Aarhus University Hospital Palle Juul-Jensens Boulevard 45, 8200 Aarhus N, Denmark Tel: +45 7846 4252 E-mail: raujen@rm.dk
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Accepted manuscript
The minimal erosive volume needed for radiographic identification of erosions in the metacarpophalangeal joints in patients with rheumatoid arthritis.
Rasmus Klose-Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, Bente Langdah, Anna Zejden, Jesper Thygesen, Kresten Krarup Keller, Ellen-Margrethe Hauge
The Journal of Rheumatology Nov 2022, jrheum.220623; DOI: 10.3899/jrheum.220623
Accepted manuscript
The minimal erosive volume needed for radiographic identification of erosions in the metacarpophalangeal joints in patients with rheumatoid arthritis.
Rasmus Klose-Jensen, Josephine Therkildsen, Anne-Birgitte Garm Blavnsfeldt, Bente Langdah, Anna Zejden, Jesper Thygesen, Kresten Krarup Keller, Ellen-Margrethe Hauge
The Journal of Rheumatology Nov 2022, jrheum.220623; DOI: 10.3899/jrheum.220623